Laurent Kodjikian, MD, PhD, speaks about the RAINBOW study, evaluating the real-life outcomes of aflibercept in a French population. Results are not far from those of international studies, and significantly better in patients who regularly received the loading dose of 3 monthly injections.

Related Articles